[57] Pollok J, JEM VA,

Carson-Chahhoud KV. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2018;**2018**:1-53

[58] Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: A literature review. Respirology. 2012;**17**(4):627-638

[59] Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. European Neuropsychopharmacology. 2022;**54**:1-6

[60] Schloer S, Brunotte L, Goretzko J, Mecate-Zambrano A, Korthals N, Gerke V, et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerging Microbes and Infections. 2020;**9**(1):2245-2255

[61] Kuykendall J. Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. Day Care & Early Education. 2000;**20**

[62] Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. Journal of Virology. 2013;**87**(11):6377-6390

[63] Bagchi P. Endoplasmic reticulum in viral infection. International Review of Cell and Molecular Biology. 2020;**350**:265-284

[64] Spack NP, Shumer DE, NJN. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Physiology & Behavior. 2017;**176**(12):139-148

[65] Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (80- ). 2020;**370**:6521

[66] Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. Journal of Pharmacological Sciences. 2015;**127**(1):6-9

[67] Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? Frontiers in Pharmacology. 2020;**11**:1-23

[68] Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatric Disease and Treatment. 2005;**1**(4):289-299

[69] Hindmarch I, Hashimoto K. Cognition and depression: The effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacology: Clinical and Experimental. 2010;**25**(2):193-200

[70] Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, et al. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2008;**32**(4):1072-1073

[71] Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. European Journal of Pharmacology. 2014;**15**(727):167-173

[72] Alonso G, Phan VL, Guillemain I, Saunier M, Legrand A, Anoal M, et al. Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system. Neuroscience. 2000;**97**(1):155-170

[73] Alshammari MA, Alshammari TK, Nenov MN, Scala F, Laezza F. Fibroblast growth factor 14 modulates the neurogenesis of granule neurons in the adult dentate gyrus. PMol Neurobiology. 2016;**53**(10):7254-7270

[74] Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nature Neuroscience. 2007;**10**(9):1110-1115

*Perspective Chapter: New Use of the SSRI Fluvoxamine in the Treatment of COVID-19 Symptoms DOI: http://dx.doi.org/10.5772/intechopen.105023*

[75] Moriguchi S, Shinoda Y, Yamamoto Y, Sasaki Y, Miyajima K, Tagashira H, et al. Stimulation of the sigma-1 receptor by DHEA enhances synaptic efficacy and neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice. PLoS One. 2013;**8**(4):e60863

[76] Ahn H, Weaver M, Lyon D, Choi E, Roger B, Fillingim P. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Physiology & Behavior. 2017;**176**(1):139-148

[77] Duman CH, Duman RS. Spine synapse remodeling in the pathophysiology and treatment of depression. Neuroscience Letters. 2015;**5**(601):20-29

[78] Castany S, Gris G, Vela JM, Verdú E, Boadas-Vaello P. Critical role of sigma-1 receptors in central neuropathic painrelated behaviours after mild spinal cord injury in mice. Scientific Reports. 2018;**8**(1):1-13

[79] Mao J, Hu Y, Ruan L, Ji Y, Lou Z. Role of endoplasmic reticulum stress in depression (Review). Molecular Medicine Reports. 2019;**20**(6):4774-4780

[80] Voronin MV, Vakhitova YV, Seredenin SB. Chaperone Sigma1R and antidepressant effect. International Journal of Molecular Sciences. 2020;**21**(7088):1-33

[81] Chen YW, Lin PY, Tu KY, Cheng YS, Wu CK, Tseng PT. Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: A meta-analysis and systematic review. Neuropsychiatric Disease and Treatment. 2015;**11**:925-933

[82] De Azevedo CT, Mondin TC, Wiener CD, Marques MB, Fucolo BDÁ, Pinheiro RT, et al. Neurotrophic factors, clinical features and gender differences in depression. Neurochemical Research. 2014;**39**(8):1571-1578

[83] Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell linederived neurotrophic factor in a rat model of depression. The International Journal of Neuropsychopharmacology. 2003;**6**(3):225-231

[84] Song C, Xiang YZ, Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: Effects of chronic ethyleicosapentaenoate treatment. The Journal of Neuroscience. 2009;**29**(1):14-22

[85] Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA. Electroconvulsive stimuli alter nerve growth factor but not brain-derived neurotrophic factor concentrations in brains of a rat model of depression. Neuropeptides. 2003;**37**(1):51-56

[86] Valdes R, Millner LM. Modulation of the Sigma-1 Receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Physiology & Behavior. 2019;**176**(3):139-148

[87] Allahtavakoli M, Jarrott B. Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, proinflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats. Brain Research Bulletin. 2011;**85**(3-4):219-224

[88] Shen YC, Wang YH, Chou YC, Liou KT, Yen JC, Wang WY, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. Journal of Neurochemistry. 2008;**104**(2):558-572

[89] Hosszu A, Antal Z, Lenart L, Hodrea J, Koszegi S, Balogh DB, et al. Σ1-receptor agonism protects against renal ischemia-reperfusion injury. Journal of American Society of Nephrology. 2017;**28**(1):152-165

[90] Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: Report of five cases. Annals of General Psychiatry. 2010;**9**:2-5

[91] Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain, Behavior, and Immunity. 2012;**26**(3):469-479

[92] Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis and Rheumatism. 2010;**62**(3):683-693

[93] Abdo SA, Wadie W, Abdelsalam RM, Khattab MM. Potential antiinflammatory effect of escitalopram in iodoacetamide-induced colitis in depressed ovariectomized rats: Role of α7-nAChR. Inflammation. 2019;**42**(6):2056-2064

[94] Obuchowicz E, Bielecka-Wajdman A, Zieliński M, MacHnik G, Gołyszny M, Ludyga T. Imipramine and venlafaxine differentially affect primary glial cultures of prenatally stressed rats. Frontiers in Pharmacology. 2020;**10**(January):1-17

[95] El Awdan SA. Anti-inflammatory, anti-nociceptive and anti-arthritic effects of antidepressants in rats. Journal of Pharma Care Health System. 2015;**4**(2):86
